tiprankstipranks
Trending News
More News >
Structure Therapeutics, Inc. Sponsored ADR (GPCR)
NASDAQ:GPCR
US Market
Advertisement

Structure Therapeutics, Inc. Sponsored ADR (GPCR) Stock Forecast & Price Target

Compare
1,035 Followers
See the Price Targets and Ratings of:

GPCR Analyst Ratings

Strong Buy
12Ratings
Strong Buy
12 Buy
0 Hold
0 Sell
Based on 12 analysts giving stock ratings to
Structure
Therapeutics, Inc. Sponsored ADR
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

GPCR Stock 12 Month Forecast

Average Price Target

$71.73
▲(271.66% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Structure Therapeutics, Inc. Sponsored ADR in the last 3 months. The average price target is $71.73 with a high forecast of $100.00 and a low forecast of $44.00. The average price target represents a 271.66% change from the last price of $19.30.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","101":"$101","35.75":"$35.8","57.5":"$57.5","79.25":"$79.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":71.73,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$71.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":44,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$44.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,35.75,57.5,79.25,101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.59,23.92923076923077,30.268461538461537,36.607692307692304,42.94692307692307,49.28615384615384,55.62538461538462,61.964615384615385,68.30384615384615,74.64307692307692,80.98230769230769,87.32153846153845,93.66076923076923,{"y":100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.59,21.754615384615384,25.91923076923077,30.083846153846153,34.24846153846154,38.41307692307692,42.5776923076923,46.74230769230769,50.90692307692308,55.071538461538466,59.23615384615384,63.40076923076923,67.56538461538462,{"y":71.73,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.59,19.62153846153846,21.653076923076924,23.684615384615384,25.716153846153844,27.747692307692308,29.779230769230768,31.810769230769232,33.84230769230769,35.87384615384615,37.90538461538462,39.93692307692308,41.96846153846154,{"y":44,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":36.43,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.13,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.19,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.14,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.94,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.12,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.97,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.75,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.79,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.33,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.79,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.51,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.59,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$100.00Average Price Target$71.73Lowest Price Target$44.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi
$60
Buy
210.88%
Upside
Reiterated
08/17/25
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Receives a Buy from Citi
BMO Capital Analyst forecast on GPCR
BMO Capital
BMO Capital
$100
Buy
418.13%
Upside
Reiterated
08/11/25
BMO Capital Remains a Buy on Structure Therapeutics, Inc. Sponsored ADR (GPCR)
H.C. Wainwright Analyst forecast on GPCR
H.C. Wainwright
H.C. Wainwright
$60
Buy
210.88%
Upside
Reiterated
08/08/25
H.C. Wainwright Keeps Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Leerink Partners Analyst forecast on GPCR
Leerink Partners
Leerink Partners
$60$44
Buy
127.98%
Upside
Reiterated
08/07/25
Structure Therapeutics price target lowered to $44 from $60 at LeerinkStructure Therapeutics price target lowered to $44 from $60 at Leerink
Citizens JMP Analyst forecast on GPCR
Citizens JMP
Citizens JMP
$89$87
Buy
350.78%
Upside
Reiterated
08/07/25
Structure Therapeutics price target lowered to $87 from $89 at Citizens JMPStructure Therapeutics price target lowered to $87 from $89 at Citizens JMP
Stifel Nicolaus Analyst forecast on GPCR
Stifel Nicolaus
Stifel Nicolaus
$50
Buy
159.07%
Upside
Reiterated
08/07/25
Stifel Nicolaus Remains a Buy on Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Guggenheim
$92$90
Buy
366.32%
Upside
Reiterated
08/06/25
Structure Therapeutics price target lowered to $90 from $92 at GuggenheimStructure Therapeutics price target lowered to $90 from $92 at Guggenheim
William Blair Analyst forecast on GPCR
William Blair
William Blair
Buy
Reiterated
08/06/25
Promising Developments in Structure Therapeutics' Clinical Trials Drive Buy Rating
Clear Street Analyst forecast on GPCR
Clear Street
Clear Street
$61
Buy
216.06%
Upside
Initiated
07/30/25
Structure Therapeutics initiated with a Buy at Clear StreetStructure Therapeutics initiated with a Buy at Clear Street
Cantor Fitzgerald Analyst forecast on GPCR
Cantor Fitzgerald
Cantor Fitzgerald
$65
Buy
236.79%
Upside
Reiterated
06/22/25
Analysts Conflicted on These Healthcare Names: BioNTech SE (NASDAQ: BNTX), Vertex Pharmaceuticals (NASDAQ: VRTX) and Structure Therapeutics, Inc. Sponsored ADR (NASDAQ: GPCR)
Jefferies Analyst forecast on GPCR
Jefferies
Jefferies
$79
Buy
309.33%
Upside
Reiterated
06/05/25
Structure Therapeutics, Inc.: Catalyst-Rich Outlook and Strategic Preparations Support Buy Rating
Piper Sandler Analyst forecast on GPCR
Piper Sandler
Piper Sandler
$93
Buy
381.87%
Upside
Reiterated
06/03/25
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Gets a Buy from Piper Sandler
Morgan Stanley Analyst forecast on GPCR
Morgan Stanley
Morgan Stanley
$118$120
Buy
521.76%
Upside
Reiterated
05/12/25
Structure Therapeutics (GPCR) PT Raised to $120 at Morgan StanleyMorgan Stanley analyst Terence Flynn raised the price target on Structure Therapeutics (NASDAQ: GPCR) to $120.00 (from $118.00) while maintaining a Overweight rating.
LifeSci Capital Analyst forecast on GPCR
LifeSci Capital
LifeSci Capital
$83
Buy
330.05%
Upside
Reiterated
05/09/25
Buy Rating for Structure Therapeutics: Promising Phase 2b Results and Strategic Market Positioning
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi
$60
Buy
210.88%
Upside
Reiterated
08/17/25
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Receives a Buy from Citi
BMO Capital Analyst forecast on GPCR
BMO Capital
BMO Capital
$100
Buy
418.13%
Upside
Reiterated
08/11/25
BMO Capital Remains a Buy on Structure Therapeutics, Inc. Sponsored ADR (GPCR)
H.C. Wainwright Analyst forecast on GPCR
H.C. Wainwright
H.C. Wainwright
$60
Buy
210.88%
Upside
Reiterated
08/08/25
H.C. Wainwright Keeps Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Leerink Partners Analyst forecast on GPCR
Leerink Partners
Leerink Partners
$60$44
Buy
127.98%
Upside
Reiterated
08/07/25
Structure Therapeutics price target lowered to $44 from $60 at LeerinkStructure Therapeutics price target lowered to $44 from $60 at Leerink
Citizens JMP Analyst forecast on GPCR
Citizens JMP
Citizens JMP
$89$87
Buy
350.78%
Upside
Reiterated
08/07/25
Structure Therapeutics price target lowered to $87 from $89 at Citizens JMPStructure Therapeutics price target lowered to $87 from $89 at Citizens JMP
Stifel Nicolaus Analyst forecast on GPCR
Stifel Nicolaus
Stifel Nicolaus
$50
Buy
159.07%
Upside
Reiterated
08/07/25
Stifel Nicolaus Remains a Buy on Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Guggenheim
$92$90
Buy
366.32%
Upside
Reiterated
08/06/25
Structure Therapeutics price target lowered to $90 from $92 at GuggenheimStructure Therapeutics price target lowered to $90 from $92 at Guggenheim
William Blair Analyst forecast on GPCR
William Blair
William Blair
Buy
Reiterated
08/06/25
Promising Developments in Structure Therapeutics' Clinical Trials Drive Buy Rating
Clear Street Analyst forecast on GPCR
Clear Street
Clear Street
$61
Buy
216.06%
Upside
Initiated
07/30/25
Structure Therapeutics initiated with a Buy at Clear StreetStructure Therapeutics initiated with a Buy at Clear Street
Cantor Fitzgerald Analyst forecast on GPCR
Cantor Fitzgerald
Cantor Fitzgerald
$65
Buy
236.79%
Upside
Reiterated
06/22/25
Analysts Conflicted on These Healthcare Names: BioNTech SE (NASDAQ: BNTX), Vertex Pharmaceuticals (NASDAQ: VRTX) and Structure Therapeutics, Inc. Sponsored ADR (NASDAQ: GPCR)
Jefferies Analyst forecast on GPCR
Jefferies
Jefferies
$79
Buy
309.33%
Upside
Reiterated
06/05/25
Structure Therapeutics, Inc.: Catalyst-Rich Outlook and Strategic Preparations Support Buy Rating
Piper Sandler Analyst forecast on GPCR
Piper Sandler
Piper Sandler
$93
Buy
381.87%
Upside
Reiterated
06/03/25
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Gets a Buy from Piper Sandler
Morgan Stanley Analyst forecast on GPCR
Morgan Stanley
Morgan Stanley
$118$120
Buy
521.76%
Upside
Reiterated
05/12/25
Structure Therapeutics (GPCR) PT Raised to $120 at Morgan StanleyMorgan Stanley analyst Terence Flynn raised the price target on Structure Therapeutics (NASDAQ: GPCR) to $120.00 (from $118.00) while maintaining a Overweight rating.
LifeSci Capital Analyst forecast on GPCR
LifeSci Capital
LifeSci Capital
$83
Buy
330.05%
Upside
Reiterated
05/09/25
Buy Rating for Structure Therapeutics: Promising Phase 2b Results and Strategic Market Positioning
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Structure Therapeutics, Inc. Sponsored ADR

1 Month
xxx
Success Rate
11/17 ratings generated profit
65%
Average Return
+7.82%
reiterated a xxx
rating 28 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 64.71% of your transactions generating a profit, with an average return of +7.82% per trade.
3 Months
xxx
Success Rate
9/17 ratings generated profit
53%
Average Return
+9.26%
reiterated a xxx
rating 28 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 52.94% of your transactions generating a profit, with an average return of +9.26% per trade.
1 Year
Evan SeigermanBMO Capital
Success Rate
4/11 ratings generated profit
36%
Average Return
-14.58%
reiterated a buy rating 24 days ago
Copying Evan Seigerman's trades and holding each position for 1 Year would result in 36.36% of your transactions generating a profit, with an average return of -14.58% per trade.
2 Years
xxx
Success Rate
2/16 ratings generated profit
13%
Average Return
-37.81%
reiterated a xxx
rating 28 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 12.50% of your transactions generating a profit, with an average return of -37.81% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GPCR Analyst Recommendation Trends

Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
13
13
16
14
13
Buy
2
2
1
1
1
Hold
0
0
0
0
0
Sell
3
2
2
0
0
Strong Sell
0
0
0
0
0
total
18
17
19
15
14
In the current month, GPCR has received 14 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. GPCR average Analyst price target in the past 3 months is 71.73.
Each month's total comprises the sum of three months' worth of ratings.

GPCR Financial Forecast

GPCR Earnings Forecast

Next quarter’s earnings estimate for GPCR is -$0.37 with a range of -$0.43 to -$0.28. The previous quarter’s EPS was -$0.36. GPCR beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.18% of the time in the same period. In the last calendar year GPCR has Outperformed its overall industry.
Next quarter’s earnings estimate for GPCR is -$0.37 with a range of -$0.43 to -$0.28. The previous quarter’s EPS was -$0.36. GPCR beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.18% of the time in the same period. In the last calendar year GPCR has Outperformed its overall industry.
No data currently available

GPCR Sales Forecast

Next quarter’s sales forecast for GPCR is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. GPCR beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.28% of the time in the same period. In the last calendar year GPCR has Preformed in-line its overall industry.
Next quarter’s sales forecast for GPCR is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. GPCR beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.28% of the time in the same period. In the last calendar year GPCR has Preformed in-line its overall industry.

GPCR Stock Forecast FAQ

What is GPCR’s average 12-month price target, according to analysts?
Based on analyst ratings, Structure Therapeutics, Inc. Sponsored ADR’s 12-month average price target is 71.73.
    What is GPCR’s upside potential, based on the analysts’ average price target?
    Structure Therapeutics, Inc. Sponsored ADR has 271.66% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is GPCR a Buy, Sell or Hold?
          Structure Therapeutics, Inc. Sponsored ADR has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Structure Therapeutics, Inc. Sponsored ADR’s price target?
            The average price target for Structure Therapeutics, Inc. Sponsored ADR is 71.73. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $100.00 ,the lowest forecast is $44.00. The average price target represents 271.66% Increase from the current price of $19.3.
              What do analysts say about Structure Therapeutics, Inc. Sponsored ADR?
              Structure Therapeutics, Inc. Sponsored ADR’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of GPCR?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis